KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Finished Goods (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Finished Goods for 13 consecutive years, with $21.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Finished Goods rose 28.44% to $21.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.1 million, a 28.44% increase, with the full-year FY2025 number at $21.1 million, up 28.44% from a year prior.
  • Finished Goods was $21.1 million for Q4 2025 at Supernus Pharmaceuticals, up from $16.7 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $46.7 million in Q3 2022 to a low of $12.5 million in Q3 2021.
  • A 5-year average of $27.6 million and a median of $29.3 million in 2023 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: surged 272.49% in 2022, then crashed 45.05% in 2024.
  • Supernus Pharmaceuticals' Finished Goods stood at $32.9 million in 2021, then increased by 6.34% to $35.0 million in 2022, then fell by 14.54% to $29.9 million in 2023, then plummeted by 45.05% to $16.4 million in 2024, then rose by 28.44% to $21.1 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Finished Goods are $21.1 million (Q4 2025), $16.7 million (Q3 2025), and $20.0 million (Q2 2025).